The exclusive license between Quark Pharmaceuticals, Inc. and Washington University is the result of a successful ongoing research relationship focused on exploring synthetic small interfering RNAs (siRNAs) compounds targeting innate immune pathway genes as inhibitors of acute lung injury.

Quark’s agreement is built on an experimental lung transplantation model developed by Professor Andrew Gelman and his colleagues at Washington University, and the use of Quark’s advanced RNAi molecules in that model. Washington University’s highly specialized expertise in pre-clinical models facilitated the characterization and optimization of the siRNA compounds.

Quark Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is a leader in the discovery and clinical development of novel therapeutics based on RNA interference (RNAi). Quark intends to advance the siRNA compounds developed together with Washington University to clinical trials for the treatment of graft dysfunction in lung transplant patients.